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BACKGROUND: Although attention-deﬁcit/hyperactivity disorder (ADHD) and eating disorders (EDs) frequently co-
occur, little is known about the shared etiology. In this study, we comprehensively investigated the genetic
association between ADHD and various EDs, including anorexia nervosa (AN) and other EDs such as bulimia nervosa.
METHODS: We applied different genetically informative designs to register-based information of a Swedish
nationwide population (N = 3,550,118). We ﬁrst examined the familial coaggregation of clinically diagnosed ADHD
and EDs across multiple types of relatives. We then applied quantitative genetic modeling in full-sisters and
maternal half-sisters to estimate the genetic correlations between ADHD and EDs. We further tested the
associations between ADHD polygenic risk scores and ED symptoms, and between AN polygenic risk scores and
ADHD symptoms, in a genotyped population-based sample (N = 13,472).
RESULTS: Increased risk of all types of EDs was found in individuals with ADHD (any ED: odds ratio [OR] = 3.97, 95%
conﬁdence interval [CI] = 3.81, 4.14; AN: OR = 2.68, 95% CI = 2.15, 2.86; other EDs: OR = 4.66, 95% CI = 4.47, 4.87;
bulimia nervosa: OR = 5.01, 95% CI = 4.63, 5.41) and their relatives compared with individuals without ADHD and
their relatives. The magnitude of the associations decreased as the degree of relatedness decreased, suggesting
shared familial liability between ADHD and EDs. Quantitative genetic models revealed stronger genetic correlation of
ADHD with other EDs (.37, 95% CI = .31, .42) than with AN (.14, 95% CI = .05, .22). ADHD polygenic risk scores
correlated positively with ED symptom measures overall and with the subscales Drive for Thinness and Body
Dissatisfaction despite small effect sizes.
CONCLUSIONS: We observed stronger genetic association with ADHD for non-AN EDs than for AN, highlighting
speciﬁc genetic correlation beyond a general genetic factor across psychiatric disorders.
Keywords: ADHD, Anorexia nervosa, Bulimia nervosa, Eating disorders, Genetic epidemiology, Polygenic risk score
https://doi.org/10.1016/j.biopsych.2019.04.036Attention-deﬁcit/hyperactivity disorder (ADHD) and eating
disorders (EDs)—including anorexia nervosa (AN) and bulimia
nervosa (BN)—signiﬁcantly impair the health and quality of life
of the affected individuals (1–4) and have been associated with
elevated premature mortality (5–9). In both clinical and popu-
lation settings, ADHD has been reported to be commonly co-
morbid with disordered eating behaviors (10–14), in particular
with binge eating–related phenotypes, compared with
restricting behaviors (13–15). In a Swedish adult sample (N =
1165) with clinically diagnosed EDs, the prevalence of ADHD
symptoms was as high as 35% to 37% in BN and AN binge
eating/purging subtype versus 18% in AN restricting subtypeª 2019 Society o
N: 0006-3223(15). ADHD symptoms during early childhood also predict
binge-eating behaviors during adolescence (16,17).
Importantly, common treatment strategies for ADHD and
binge eating–related symptoms exist. For instance, a stim-
ulant medication, lisdexamfetamine, with well-established
beneﬁcial effects on ADHD symptoms (18), has been
shown to be effective in the short-term management of
binge eating disorder (19) and to reduce the risk of binge
eating relapse over 6 months (20). Stimulant medication is
under consideration for the treatment of BN as well (15),
warranting reﬁned understanding of the shared etiology
between ADHD and EDs.f Biological Psychiatry. This is an open access article under the
CC BY license (http://creativecommons.org/licenses/by/4.0/).
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ADHD and EDs: Genetic Associations in a Large Population
Biological
PsychiatryThe genetic liability for ADHD and EDs has been established
separately by twin and family studies (21–24) and genome-
wide association studies (GWASs); single nucleotide poly-
morphism (SNP) heritability was .22 (SE = .01) for ADHD (25)
and .20 (SE = .02) for AN (26), but the genetic overlap re-
mains unclear. The available GWAS ﬁndings revealed a
nonsigniﬁcant genetic correlation between ADHD and AN that
was difﬁcult to interpret owing to the low statistical power (27).
GWASs for non-AN EDs are not available, and only one twin
study has reported a moderate genetic correlation (.35) be-
tween self-reported non-AN EDs (i.e., binge eating behaviors)
and ADHD symptoms in a Swedish adult twin sample (28).
Replications at population level with clinically stringent deﬁni-
tions for both ADHD and disordered eating are needed.
Although shared heritability has been reported across mul-
tiple psychiatric disorders (27,29,30), it has not been obvious
for ADHD and EDs. Moreover, various EDs might be genetically
differently associated with ADHD given their differential
phenotypic associations [e.g., binge eating behaviors are
more correlated with ADHD compared with restricting behav-
iors (13–15)] and warrant further investigation. We used mul-
tiple complementary approaches to comprehensively explore
the phenotypic and genetic associations between ADHD and
various EDs at both diagnostic and symptomatic levels. With
the Swedish national register data, we ﬁrst examined the fa-
milial coaggregation of clinically diagnosed ADHD and EDs,
speciﬁcally AN and other EDs (OEDs), including BN. We then
applied quantitative genetic modeling to estimate the genetic
and environmental correlations between ADHD and EDs. Next,
we incorporated GWAS ﬁndings and symptom measures in a
child and adolescent twin sample, the Child and Adolescent
Twin Study in Sweden (CATSS), where we derived polygenic
risk scores (PRSs) for ADHD and AN separately and estimated
the associations between ADHD PRSs and ED symptoms and
between AN PRSs and ADHD symptoms, respectively.
Convergent results across these methodologies would allow
us to draw more deﬁnitive conclusions regarding the nature of
the relation between ADHD and EDs.METHODS AND MATERIALS
The use of the Swedish national registers and CATSS was
approved by the Regional Ethics Review Board in Stockholm,
Sweden. In the CATSS, informed consent was provided by
parents (for twins aged 9 or 12 years) and by twins themselves
(aged 15 years) (31).
Data Sources
The Swedish National Registers. Using the unique in-
dividual identiﬁcation numbers, we linked several registers in
Sweden (data updated until December 2013). We acquired
information on birth year, death date, and migration type and
date from the Total Population Register (32); clinically diag-
nosed ADHD and EDs from the National Patient Register
(based on the ICD-9 or ICD-10) (33), Prescribed Drug Register
(34), and several treatment quality registers (based on the
DSM-IV) (35–38); and familial relatedness from the Multi-
Generation Register. The description of these registers is
detailed in the Supplement.2 Biological Psychiatry - -, 2019; -:-–- www.sobp.org/journalWe identiﬁed ADHD based on registered lifetime diagnosis
and medication prescriptions (23) and identiﬁed EDs (including
any ED, AN, OED, and BN) based on lifetime diagnosis (9)
(detailed in Supplement). Any ED, AN, and BN were deﬁned
as in previous research (9). OED was deﬁned as having any
lifetime ED other than AN (i.e., non-AN ED).
Child and Adolescent Twin Study in Sweden. CATSS
is an ongoing study (since 2004) targeting all twins born in
Sweden since July 1, 1992 (31) (data updated until December
2015). Parent reports on mental health of the twins were
collected when the twins were 9 years old (born 1995–2005) or
12 years old (born 1992–1995). Follow-up questionnaires were
distributed to both parents and twins when the twins reached
15 and 18 years of age. Genotype data were available for
13,472 individuals after standard data processing and quality
control (Supplement).
Parent-reported ADHD symptoms were measured with a
validated instrument, the Autism–Tics, ADHD, and Other
Comorbidities inventory (39), at 9 or 12 years of age. The
ADHD measures contained 19 items, with subscales of Inat-
tention (9 items) and Hyperactivity/impulsivity (10 items).
Questions were answered on a scale of “no” (coded 0), “yes, to
some extent” (coded 0.5), and “yes” (coded 1) (31). Self-
reported ED symptoms were measured by 3 of 11 subscales
in the Eating Disorder Inventory-2 (EDI-2) (40), validated in
Nordic countries in female individuals (41,42), at 15 years of
age, including the subscales of Drive for Thinness (7 items),
Bulimia (7 items), and Body Dissatisfaction (8 items). Questions
were answered on a scale with 6 options ranging from “never”
(coded 1) to “always” (coded 6). We computed the sum score
of the ADHD symptom questions and mean score of EDI-2
questions at both full scale and subscales (score distribu-
tions detailed in Supplemental Figure S1).
Statistical Analysis
Associations Between ADHD and EDs and Familial
Coaggregation. Analyses were performed in a Swedish
nationwide population born in Sweden between 1970 and
2005 after excluding individuals who died or emigrated before
6 years of age and adoptees (N = 3,550,118; age range = 8–44
years, mean = 26.6, SD = 10.3). To study familial coag-
gregation, we used data for full-siblings (4,191,852 pairs),
maternal half-siblings (697,763 pairs), paternal half-siblings
(829,126 pairs), and cousins (16,347,002 pairs).
We ﬁrst estimated odds ratios (ORs) of any ED, AN, OED,
and BN in individuals with ADHD compared with individuals
without ADHD using logistic regression. We then evaluated
familial coaggregation patterns of ADHD and EDs by esti-
mating ORs of EDs in each type of relative of individuals with
ADHD compared with the same type of relative of individuals
without ADHD. If ADHD and EDs share genetic and/or family
environmental causes, ORs of EDs would be above 1 in rela-
tives of individuals with ADHD (i.e., familial coaggregation). We
adjusted for birth year and sex and addressed nonindepen-
dence of data due to familial clustering with robust (sandwich)
estimator of standard errors in all regression models. We
further adjusted for ADHD in the relatives as sensitivity tests
(9,43) (Supplement).
Table 1. Descriptive Statistics of the Total Study Population and Each Type of Relative
Total Population (N = 3,550,118) Female Individuals (n = 1,726,311) Male Individuals (n = 1,823,807)
ADHD No ADHD ADHD No ADHD ADHD No ADHD
Number % Number % Number % Number % Number % Number %
Total 108,443 3,441,675 38,339 1,687,972 70,104 1,753,703
Any ED 2887 2.7 30,030 0.9 2588 6.8 28,260 1.7 299 0.4 1770 0.1
AN 998 0.9 14,217 0.4 916 2.4 13,425 0.8 82 0.1 792 0.0
OEDs 2586 2.4 22,962 0.7 2323 6.1 21,659 1.3 263 0.4 1303 0.1
BN 741 0.7 7090 0.2 709 1.8 6938 0.4 32 0.0 152 0.0
ADHD, attention-deﬁcit/hyperactivity disorder; AN, anorexia nervosa; BN, bulimia nervosa; ED, eating disorder; OEDs, other eating disorders
(i.e., non-AN eating disorders).
ADHD and EDs: Genetic Associations in a Large Population
Biological
PsychiatryQuantitative Genetic Modeling. We used full-sisters and
maternal half-sisters for the quantitative genetic analyses.
Because the prevalence of EDs was too low in male in-
dividuals, we restricted the analyses to female individuals. We
randomly selected one pair of full-sisters or maternal half-
sisters from each family, resulting in 334,433 pairs of full-
sisters (age range = 9–44 years, mean = 26.5, SD = 9.6) and
57,036 pairs of maternal half-sisters (age range = 9–44 years,
mean = 26.2, SD = 9.3). Twin pairs were excluded because
their genetic and/or environmental sharing was potentially
higher than that of full-sisters who were not twins.
Each binary trait (i.e., ADHD, AN, OED, or BN) was analyzed
in a liability threshold setting (44). We ﬁrst estimated tet-
rachoric correlations, including within-trait cross-sister,
phenotypic (i.e., cross-trait within-individual), and cross-trait
cross-sister correlations (Supplement). Next, bivariate quanti-
tative genetic models were ﬁtted to quantify genetic and
environmental contributions to ADHD and EDs and their as-
sociations. Analyses were performed using OpenMx (version
2.7.9) in R 3.3.2 (45). Quantitative genetic modeling de-
composes variance of each disorder and covariance between
two disorders into additive genetic effects (A), dominant ge-
netic effects (D), shared environmental effects (C), and unique
environmental effects (E, including measurement error). On
average, full-sisters share additive (coefﬁcient .50) and domi-
nant (coefﬁcient .25) genetic variance and shared (coefﬁcient
1.00) environment variance, whereas maternal half-sisters
share additive (coefﬁcient .25) genetic variance and shared
(coefﬁcient 1.00) environment variance. For each combination
of ADHD and ED, we ﬁtted bivariate models that included A, C,
and E components (ACE model), A, D, and E components (ADE
model), and A and E components (AE model) and interpreted
results of the best-ﬁt model (measured by the lowest Akaike
information criterion. The main results included heritability,
coheritability (the proportion of the phenotypic covariance
explained by the genetic covariance), and the genetic corre-
lation for ADHD and ED.
Molecular Genetic Approach Using PRSs. We derived
ADHD and AN PRSs for 13,472 eligible individuals in CATSS
using imputed genetic data (Supplement). ADHD PRSs were
generated based on independent summary statistics from the
largest available GWAS of clinically diagnosed ADHD (19,099
cases and 34,194 controls, European ancestry) (46). We fol-
lowed standard procedure (25) and derived ADHD PRSs based
on 84,969 SNPs after linkage disequilibrium clumping (r2 . .1Bwithin 1000 kb; with minor allele frequency $ 0.05 and
acceptable imputation quality INFO $ 0.80) using 1000 ge-
nomes (European ancestry) as reference (47). AN PRSs in
CATSS were derived using independent summary statistics of
the largest available AN GWAS (3495 cases and 10,982 con-
trols, European ancestry; 84,278 SNPs after linkage disequi-
librium clumping with the above parameters) (26). PRSs were
calculated in each individual by scoring the number of refer-
ence alleles (weighted by the allelic effect size) across the set
of remaining SNPs after clumping (PLINK 1.9; http://pngu.mgh.
harvard.edu/purcell/plink/) (48). We derived and standardized
ADHD and AN PRSs at the p-value threshold p , 1.00 and
used them for primary analyses (49); PRSs at stricter thresh-
olds (p , .00001, p , .001, p , .01, p , .05, p , .10, and p ,
.50) were derived and standardized for sensitivity analyses.
We evaluated the associations between ADHD PRSs and
the ED symptom score (dependent variable) and between AN
PRSs and the ADHD symptom score (dependent variable)
using linear regressions, adjusted for sex, birth year, and the
top 5 principal components; variance in symptom score
explained by PRSs was measured by the difference in R2
between the full model and the nested model without PRSs.
To account for the correlated nature of the data, we applied
generalized estimating equations to estimate the regression
coefﬁcients (b) and the standard error [R package drgee (50)].
b can be interpreted as the change in the symptom score
per standard deviation of PRS. We stratiﬁed analyses by sex
in sensitivity analyses.
RESULTS
The prevalence of ADHD was 3.1% in the Swedish nationwide
population (N = 3,550,118; 2.2% in female individuals and
3.8% in male individuals) during the observed period. As
shown in Table 1, individuals with ADHD had signiﬁcantly
higher prevalence of EDs than individuals without ADHD; the
prevalence of all EDs in the study population during the
observed period was higher in female individuals than in male
individuals and was stable across different types of relatives
(Supplemental Table S1).
Associations Between ADHD and EDs and Familial
Coaggregation
In both sexes, individuals with ADHD had increased risk of any
ED (female OR = 3.95, 95% conﬁdence interval [CI] = 3.78, 4.12;
male OR = 3.88, 95% CI = 3.41, 4.42). The ORs of OEDsiological Psychiatry - -, 2019; -:-–- www.sobp.org/journal 3
Table 2. Numbers, Correlations, and Results in Quantitative Genetic Modeling for ADHD and ED (AN, OEDs, and BN)
Number of Individuals or Pairs Correlation Results of Quantitative Genetic Modeling
Within Disorder ED and ADHD Within Disorder ED and ADHD
Proportion of Variance
Within Disorder Explained
(95% CI)
Proportion of Covariance
With ADHD Explained
(95% CI)
Correlations
With ADHD
(95% CI)
Concordant
Pairsa (Both
Affected/Both
Unaffected)
Discordant
Pairsb
With
Both
Disorders
Concordant
Pairsc
Within-Trait
Cross-Sister
Correlation
(95% CI)
Phenotypic
Correlation
With ADHD
(95% CI)
Cross-Trait
Cross-Sister
Correlation
With ADHD
(95% CI)
Additive
Genetic (A)
Unique
Environmental
(E)
Additive
Genetic
(A)
Unique
Environmental
(E)
Additive
Genetic
(A)
Unique
Environmental
(E)
ADHD Full-sister 787/322,529 11,117 – – .41 (.39, .42) – – .82 (.78, .85) .18 (.15, .22) – – – –
Maternal
half-
sister
292/52,031 4713 – – .22 (.19, .25) – –
AN Full-sister 107/328,436 5890 343 150 .21 (.18, .25) .19 (.17, .21) .04 (.04, .04) .42 (.35, .49) .58 (.52, .65) .42 (.16, .69) .58 (.31, .84) .14 (.05, .22) .33 (.18, .48)
Maternal
half-
sister
5/56,103 928 99 44 .03 (2.10, .15) .17 (.13, .21) .004 (2.05, .06)
OEDs Full-sister 250/324,912 9271 853 331 .23 (.20, .25) .31 (.30, .33) .11 (.09, .13) .44 (.39, .49) .56 (.51, .61) .73 (.60, .85) .27 (.15, .40) .37 (.31, .42) .26 (.14, .38)
Maternal
half-
sister
19/55,133 1884 286 107 .02 (2.05, .10) .28 (.25, .31) .04 (.01, .08)
BN Full-sister 34/331,325 3074 273 87 .20 (.16, .24) .28 (.26, .30) .07 (.07, .07) .40 (.35, .51) .60 (.50, .70) .58 (.35, .81) .42 (.19, .65) .28 (.20, .39) .33 (.15, .53)
Maternal
half-
sister
4/56,461 571 79 37 .13 (2.02, .27) .23 (.19, .28) .07 (.01, .13)
Correlations were tetrachoric correlations (presented with 95% CI). Within-trait cross-sister correlations were the tetrachoric correlations of a disorder between two sisters in a pair.
Phenotypic correlations with ADHD were the tetrachoric correlations between ADHD and ED within an individual. Cross-sister cross-trait correlations with ADHD were the tetrachoric
correlations between ADHD in one sister and ED in the other sister in a pair. Results are from three bivariate AE models for ADHD–AN, ADHD–OEDs, and ADHD–BN. Results are
presented as point estimates (95% CI). ADHD heritability was estimated in each combination of ADHD and ED, and the estimates were similar. The presented heritability and variance
explained by unique environmental variance were extracted from the bivariate AE model of ADHD–OED, which was the best powered model compared with the other two models. The
heritability of ADHD was estimated to be approximately 82%, and the heritabilities of the EDs were estimated to be approximately 40% to 45%. Approximately 42% of the phenotypic
covariance between ADHD and AN was explained by their genetic covariance, whereas approximately 73% of the phenotypic covariance between ADHD and OEDs was explained by
their genetic covariance, and the proportion for ADHD and BN was estimated to be approximately 58%. The remaining proportion of the phenotypic covariance between ADHD and each
ED was explained by their unique environmental covariance. The genetic correlation between ADHD and AN was estimated to be approximately .14 (.05, .22), whereas higher genetic
correlation with ADHD was found in OEDs (.37 [.31, .42]) and potentially also in BN (.28 [.20, .39]).
ADHD, attention-deﬁcit/hyperactivity disorder; AN, anorexia nervosa; BN, bulimia nervosa; CI, conﬁdence interval; ED, eating disorder; OEDs, other eating disorders (i.e., non-AN eating
disorders).
aThe number of pairs with both sisters affected vs. (/) the number of pairs with both sisters unaffected.
bThe number of pairs where one sister was affected with the disorder and the other was unaffected.
cThe number of pairs where one sister was affected with ADHD and the other affected with ED.
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Figure 1. Odd ratios (ORs) of eating disorders
(EDs) in individuals with attention-deﬁcit/
hyperactivity disorder (ADHD) and their relatives
compared with individuals without ADHD and their
relatives. The forest plot shows the ORs of any ED,
anorexia nervosa (AN), other EDs (i.e., non-AN EDs)
(OED), and bulimia nervosa (BN) in index individuals
with ADHD and their relatives compared with index
individuals without ADHD and their relatives. In
general, greater ORs were found in more closely
(genetically and familial environmentally) related
relatives, suggesting shared genetic and/or familial
environmental liabilities between ADHD and these
EDs. In general, the ORs appeared to be higher for
OED and BN compared with AN in each type of
relative, suggesting stronger associations with
ADHD in OED and BN than in AN. Bolded values are
signiﬁcant at p , .0001. CI, conﬁdence interval.
ADHD and EDs: Genetic Associations in a Large Population
Biological
Psychiatry(female = 4.63, 95%CI = 4.42, 4.84; male = 4.57, 95%CI = 3.98,
5.26) and BN (female = 4.94, 95% CI = 4.56, 5.35; male = 7.30,
95% CI = 4.87, 10.94) were higher than the OR of AN (female =
2.70, 95%CI = 2.52, 2.90; male = 2.29, 95%CI = 1.82, 2.89); sex
difference was not statistically signiﬁcant (SupplementalTable 3. Associations Between ADHD PRS and ED Symptom Me
Individuala,
n (%)
Symptom
Measures,
Mean (SD)
ADHD PRS and ED Symptom Measures
EDI-2 full scale (range: 1–5.8) 5680 (42.2) 2.1 (0.77)
Drive for Thinness (range: 1–6) 5674 (42.1) 2.1 (0.98)
Bulimia (range: 1–6) 5668 (42.1) 1.5 (0.57)
Body Dissatisfaction (range: 1–6) 5679 (42.2) 2.6 (1.13)
AN PRS and ADHD Symptom Measures
ADHD full scale (range: 0–19) 13,451 (99.8) 1.8 (2.89)
Inattention (range: 0–9) 13,454 (99.9) 1.0 (1.65)
Impulsivity/hyperactivity (range: 0–10) 13,455 (99.9) 0.9 (1.57)
The table shows the results of the primary analysis, where ADHD PRS an
after linkage disequilibrium clumping (p-value threshold , 1) and standar
symptom measures of Drive for Thinness (p = .022), Body Dissatisfaction
associated with the measure of Bulimia. R2 represents the proportion of
PRS; for example, the variance in ADHD PRS explained approximately 0
approximately 0.13% variance in the measure of Body Dissatisfaction (R2
measures per standard deviation increase of the PRS; for example, when
would increase by 0.032 points for Drive for Thinness, by 0.042 for Bod
signiﬁcantly associated with any of the symptom measures of ADHD. Sta
consistency within each (sub)scale; higher values correspond to higher inte
ADHD, attention-deﬁcit/hyperactivity disorder; AN, anorexia nervosa;
Inventory-2; PRSs, polygenic risk scores.
aThe total number (%) of individuals with each symptom measure in the
BTable S2), with ORs in female and male individuals being com-
parable (Supplemental Table S3). We combined data from both
sexes for familial coaggregation analyses tomaximize statistical
power. Full-siblings of individuals with ADHD were at increased
risk of any ED (OR = 1.44, 95% CI = 1.36, 1.52), AN (OR = 1.18,asures and Between AN PRS and ADHD Symptom Measures
Cronbach’s
Alpha
Regression
Coefﬁcient,
b (95% CI)
p
Value R2
.92 .027 (.005, .049) .015 .0012
.89 .032 (.005, .059) .022 .0010
.72 .004 (2.013, .021) .654 .0000
.90 .042 (.011, .072) .007 .0013
.96 2.049 (2.101, .002) .062 .0003
.94 2.029 (2.058, .000) .053 .0003
.93 2.021 (2.049, .007) .145 .0002
d AN PRS were derived based on all single nucleotide polymorphisms
dized before analysis. ADHD PRSs were signiﬁcantly associated with
(p = .007), and the full scale (p = .015), but they were not signiﬁcantly
variance in the symptom measures explained by the variance in the
.1% variance in the measure of Drive for Thinness (R2 = .0010) and
= .0013). Regression coefﬁcient (b) reﬂects the change in symptom
ADHD PRS increased by 1 standard deviation, the symptom measure
y Dissatisfaction, and by 0.027 for the full scale. AN PRS was not
ndardized Cronbach’s alpha was presented as a measure for internal
rnal consistency. The range for acceptable values was .70 to .95.
CI, conﬁdence interval; ED, eating disorder; EDI-2, Eating Disorder
study population (N = 13,472) is shown.
iological Psychiatry - -, 2019; -:-–- www.sobp.org/journal 5
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Figure 2. Variance explained (R2) and regression coefﬁcient (b) for the association between attention-deﬁcit/hyperactivity disorder (ADHD) polygenic risk
scores (PRSs) and eating disorder (ED) symptoms and the association between anorexia nervosa (AN) PRSs and ADHD symptoms. (A, B) Associations
between ADHD PRSs and Eating Disorder Inventory-2 (EDI-2) measures of ED symptoms. Panel (A) shows R2, and panel (B) shows b and 95% conﬁdence
interval (CI). ADHD PRSs across different p-value thresholds showed consistent results in explaining the variance (A) and consistent regression coefﬁcients (B)
in each measure of the ED symptoms. (C, D) Associations between AN PRSs and Autism–Tics, ADHD, and Other Comorbidities inventory (A-TAC) measures
for ADHD symptoms. Panel (C) shows R2, and panel (D) shows b and 95% CI. Variance explained (C) and regression coefﬁcients (D) were less consistent for
the associations between AN PRSs and ADHD. AN PRSs across multiple p-value thresholds were not signiﬁcantly associated with measures of ADHD
symptoms in general, although AN PRSs at p-value thresholds p, .00001, p, .01, and p, .05 showed negative associations with the measure of Inattention
(p , .05). ADHD_pT, p-value thresholds for ADHD PRSs; AN_pT, p-value thresholds for AN PRSs. PRSs at threshold p, 1.00 were used for the main analysis.
PRSs at other p-value thresholds were used for sensitivity tests. *p # .05 and **p # .01 for the associations between PRSs and the symptom measures.
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Psychiatry95%CI=1.08, 1.29), OEDs (OR=1.58, 95%CI =1.49, 1.68), and
BN (OR = 1.44, 95%CI = 1.29, 1.61) compared with full-siblings
of individuals without ADHD (Figure 1). Other relatives of in-
dividuals with ADHD were also at increased risk of EDs and
the magnitude of ORs was attenuated with decreasing ge-
netic and/or familial environmental relatedness, suggesting
familial liability shared between ADHD and EDs. Familial
coaggregation remained statistically signiﬁcant for ADHD
and any ED and OED after adjusting for ADHD in relatives,
further supporting the shared familial liabilities (Supplemental
Table S4).6 Biological Psychiatry - -, 2019; -:-–- www.sobp.org/journalQuantitative Genetic Modeling
The ORs of EDs in the quantitative genetic modeling sample
were comparable to those in the female population
(Supplemental Table S3). AE models had the lowest Akaike
information criterion (Supplemental Table S5) and were there-
fore interpreted (Table 2).
As shown in Table 2, within-trait cross-sister correlations for
ADHD, AN, OEDs, and BN were higher in full-sisters than in
maternal half-sisters, suggesting genetic effects on each dis-
order given that the two types of sisters were assumed to have
equal environmental sharing but that full-sisters share more
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Psychiatrygenetic variance than maternal half-sisters. Heritability was
estimated to be 82% in ADHD, 42% in AN, 45% in OEDs, and
40% in BN from the AE models.
The phenotypic correlation between ADHD and each ED
was comparable between sister types; OEDs manifested
higher phenotypic correlation with ADHD than AN, which
agreed with the observed pattern of ORs of OEDs and AN in
individuals with and without ADHD. The cross-trait cross-sister
correlations between ADHD and EDs were also higher in full-
sisters than in maternal half-sisters, suggesting genetic ef-
fects on the association between ADHD and each ED. The
coheritability with ADHD was estimated to be 73% for OEDs,
suggesting that 73% of the phenotypic covariance between
OEDs and ADHD was explained by genetic covariance of the
two disorders. Approximately 58% of the phenotypic covari-
ance between BN and ADHD and 42% of the phenotypic
covariance between AN and ADHD were attributable to their
genetic covariance. Genetic correlation with ADHD was
numerically higher in OEDs (.37, 95% CI = .31, .42), and
potentially in BN (.28, 95% CI = .20, .39), than in AN (.14, 95%
CI = .05, .22).
PRS Analysis
The subscales of ADHD and ED symptoms showed high in-
ternal consistency except the subscale Bulimia [Cronbach’s
alpha (51)] (Table 3). ADHD PRSs were signiﬁcantly associated
with the EDI-2 full scale (b = .027, 95% CI = .005, .049, R2 =
.0012, p = .015) and the subscales Drive for Thinness (b = .032,
95% CI = .005, .059, R2 = .0010, p = .022) and Body Dissat-
isfaction (b = .042, 95% CI = .011, .072, R2 = .0013, p = .007)
but not the subscale Bulimia (b = .004, 95% CI = 2.013, .021,
p = .654) (Table 3). In contrast, AN PRSs were not signiﬁcantly
associated with ADHD full scale or the subscales.
The sensitivity analyses of ADHD PRSs at different p-value
thresholds showed consistency in variance explained
(Figure 2A) and regression coefﬁcient (Figure 2B) for all EDI-2
measures; the associations appeared to be stronger in fe-
male individuals, but sex differences were not statistically
signiﬁcant (Supplemental Table S7). The associations between
AN PRSs and ADHD symptoms were less consistent. AN PRSs
at the p-value thresholds p , .00001, p , .01, and p , .05
showed weak negative associations with the subscale Inat-
tention (Figure 2C, D), which might be driven by male in-
dividuals who had higher variation in the symptoms than
female individuals (Supplemental Tables S8 and S9 and
Supplemental Figures S2 and S3).
DISCUSSION
Although genetic correlations are found across several psy-
chiatric disorders (27,30), little is known about how various EDs
genetically correlate with other disorders, speciﬁcally ADHD,
given their common clinical co-occurrence (11,12,15,16). Here
we reported convergent results from different genetically
informative study designs revealing the genetic associations
with ADHD across various EDs, especially non-AN EDs
compared with AN, highlighting speciﬁc genetic correlations
beyond a general genetic factor across psychiatric disorders
(29). Our ﬁnding of marked genetic correlations between ADHD
and non-AN EDs was in line with a previously found geneticBcorrelation between ADHD symptoms and binge eating be-
haviors (28) and might in part explain the stronger associations
of ADHD with binge eating–related symptoms than with
restrictive symptoms (13–15,17). We further found that com-
mon genetic risk variants for ADHD were signiﬁcantly associ-
ated with ED symptoms, which was also consistent with our
familial coaggregation and quantitative genetic ﬁndings. Our
results enhance the understanding of why EDs and ADHD co-
occur and underscore the importance of screening for co-
morbid symptoms in individuals with EDs and ADHD.
To explore the genetic overlap, we used 3 analytical ap-
proaches: familial coaggregation analysis, quantitative genetic
modeling, and a molecular genetic approach using PRSs.
Converging evidence across different methods strengthens
the support for a genetic overlap between ADHD and EDs. It
also demonstrates that the genetic associations with ADHD
are present not only in clinically diagnosed EDs (which may
represent the extreme end of a symptom spectrum) but also in
dimensional ED traits in the general population. The ﬁndings
complement discussions about the categorical versus dimen-
sional conceptualizations of mental disorders (30,52) and show
the value in using both types of measures in genomic research.
Our ﬁndings have important clinical implications. First, the
observed associations and familial coaggregation patterns be-
tween ADHD and EDs suggest that family history may help with
early detection and risk identiﬁcation of the two disorders.
ADHD has been shown to predict ED symptoms (16); regular
screening for ADHD symptoms in those with EDs and for ED
symptoms in those with ADHD may hasten detection of and
appropriate intervention for comorbid conditions. When inter-
preting the estimated ORs, it is important to acknowledge that
other comorbidities were not accounted for because the
adjustment could introduce bias (53) owing to the complex yet
unclear interdependencies between disorders. Second, our
ﬁndings marked stronger phenotypic and genetic correlations
with ADHD in non-AN EDs comparedwith AN, implying different
etiologies and potential treatment strategies among patients
with ADHD with different comorbid ED conditions. Stimulant
medication has been shown to be effective in both ADHD (18)
and binge eating disorder (19,20), and applying stimulant
medication to treat BN is under consideration (15). Our ﬁnding of
shared genetic underpinnings of ADHD and non-AN EDs may
provide further support for common treatment strategies for the
two disorders. Third, recent studies have reported an associa-
tion between ADHD and obesity (54–56), and disordered eating
has been hypothesized to affect this association (57,58). Shared
etiology of ADHD and disordered eating implied by our study
may support this hypothesis and encourages more detailed
investigation to determine the extent to which disordered eating
contributes to obesity in individuals with ADHD.
The genetic overlap between ADHD and EDs may in part
reﬂect a more general genetic susceptibility to psychopathol-
ogy (29,59). Our ﬁnding that the genetic sharing of ADHD was
stronger with non-AN EDs than with AN does, nevertheless,
support genetic speciﬁcity beyond such a general genetic
factor. For instance, genetic factors underlying (food-related)
impulsivity (60) might be of speciﬁc importance for the
observed genetic overlap between ADHD and non-AN EDs.
How BN PRSs correlate with different subscales of ADHD will
be of value once BN GWASs become available.iological Psychiatry - -, 2019; -:-–- www.sobp.org/journal 7
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associated with the phenotype measures, their effect sizes
were generally small, possibly owing to 1) PRSs being based
on tagged but not necessarily causal SNPs, 2) polygenic
measures possibly not reﬂecting more complex genetic ar-
chitecture (61), and 3) the effect of each genetic variant being
estimated with error, which may be improved with increased
discovery sample size [as seen in schizophrenia (62)]. These
may also explain the discrepancy between our results of
positive ADHD–AN genetic correlation and the nonsigniﬁcant
association between AN PRSs and ADHD symptoms, which
was nevertheless consistent with previous genomic ﬁndings
(27). Increased proportion of phenotypic variance explained by
PRSs is anticipated with increased discovery sample sizes and
PRSs that better capture causal genetic effects.
Limitations need to be considered. First, register-based data
captured only treatment-seeking individuals. Individuals who
had EDs but did not seek treatment were therefore misclassiﬁed
in our study. BN was not identiﬁable in the Swedish version of
ICD-9, resulting in additional misclassiﬁcation. If the misclas-
siﬁcation of EDs was differential for ADHD diagnosis (e.g., the
diagnosis of ADHD increased the chance for discovering EDs in
the individual) and vice versa, the associations between ADHD
and EDs might be overestimated. Nevertheless, the diagnosis
of ADHD was less likely to inﬂuence the chance of discovering
EDs in a relative, so the estimated familial coaggregation might
be less biased. Second, the EDI-2 subscale Bulimia had low
internal consistency and low variation, which might be due to
the fact that participants in the CATSS (15 years old) might have
not yet developed pathological binge eating behaviors that
typically begin during late adolescence or early adulthood
(35,63). Third, the study was underpowered to perform the
quantitative genetic modeling in male individuals. Better
detection of EDs and/or continuous symptommeasures in male
individuals might provide sufﬁcient statistical power for the
analyses inmale individuals and examination of sex differences.
In conclusion, using 3 convergent methodological ap-
proaches, we observed signiﬁcant genetic associations be-
tween clinically diagnosed ADHD and EDs as well as
dimensional measures of ED pathology. The genetic associa-
tion with ADHD was stronger in non-AN EDs compared with
AN, highlighting speciﬁc genetic correlations beyond a general
genetic factor across psychiatric disorders. We expect that as
genetic sample sizes grow, PRSs will become more robust and
the next iteration of PRS analyses will have greater statistical
power. Nonetheless, our convergent results encourage clinical
vigilance for copresentation of EDs (especially non-AN EDs)
and ADHD and suggest that, at least in part, the observed
association between these 2 presentations is due to shared
genetic factors.
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